Literature DB >> 8832524

Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status.

G Marcoullis1, J Mehta, J Treleaven.   

Abstract

Autologous bone marrow and peripheral blood stem cell transplants permit the use of higher doses of chemoradiotherapy than would have been possible without "rescuing' bone marrow function. This may well allow cure of malignant disorders in cases where this was previously not feasible. This short review attempts to summarize the current status of such a treatment approach for the various haematological malignancies.

Entities:  

Mesh：

Year:  1995        PMID： 8832524     DOI： 10.1007/bf02990566

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  82 in total

1.  Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia.

Authors:  A M Yeager; G B Vogelsang; R J Jones; E R Farmer; V Altomonte; A D Hess; G W Santos
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

2.  Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells.

Authors:  J Mehta; R Powles; S Singhal; J Treleaven
Journal:  Bone Marrow Transplant       Date:  1995-04       Impact factor: 5.483

3.  Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol.

Authors:  A M Carella; P Carlier; A Congiu; D Occhini; S Nati; G Santini; D Pierluigi; D Giordano; A Bacigalupo; E Damasio
Journal:  Bone Marrow Transplant       Date:  1991-08       Impact factor: 5.483

4.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.

Authors:  R A Zittoun; F Mandelli; R Willemze; T de Witte; B Labar; L Resegotti; F Leoni; E Damasio; G Visani; G Papa
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

5.  Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants.

Authors:  L B To; M M Roberts; D N Haylock; P G Dyson; A L Branford; D Thorp; J Q Ho; G W Dart; N Horvath; M L Davy
Journal:  Bone Marrow Transplant       Date:  1992-04       Impact factor: 5.483

6.  Consequences of cryopreserving first remission autologous marrow for use after relapse in patients with acute myeloid leukemia.

Authors:  K Schiffman; R Clift; F R Appelbaum; J Sanders; W Bensinger; F B Petersen; S Rowley; R Hill; P Martin; R Storb
Journal:  Bone Marrow Transplant       Date:  1993-03       Impact factor: 5.483

7.  Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups.

Authors:  P B McGlave; P De Fabritiis; A Deisseroth; J Goldman; M Barnett; J Reiffers; B Simonsson; A Carella; D Aeppli
Journal:  Lancet       Date:  1994-06-11       Impact factor: 79.321

8.  Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia.

Authors:  A Zomas; J Mehta; R Powles; J Treleaven; T Iveson; S Singhal; B Jameson; B Paul; S Brincat; D Catovsky
Journal:  Bone Marrow Transplant       Date:  1994-11       Impact factor: 5.483

9.  Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.

Authors:  H M Kantarjian; M Talpaz; J Hester; E Feldman; M Korbling; J Liang; M B Rios; T L Smith; L Calvert; A B Deisseroth
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

10.  High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting.

Authors:  P Corradini; C Voena; M Astolfi; M Ladetto; C Tarella; M Boccadoro; A Pileri
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.